Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01071083 · ClinicalTrials.gov registry record · Phase 2
Treatment Interruption of Natalizumab
A Phase 2 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
NCT01071083 is a Phase 2 study that has completed, run by Biogen. The registered enrollment target is 175 participants.
The verdict
NCT01071083, a Phase 2 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
Study Summary
This is a randomized, rater blinded trial in patients who interrupt treatment with natalizumab with or without being treated with other immunomodulatory drugs, or continue treatment with natalizumab. The main purpose of this study is to find out the following, when participants stop taking natalizumab for 24 weeks: * when MS symptoms return, and * if other drugs for MS may help control MS symptoms during the natalizumab-interruption period. This study will also explore how quickly the effects of natalizumab return after resuming natalizumab dosing.
Interventions
- DRUG methylprednisolone
- DRUG natalizumab
- OTHER IV placebo
- DRUG glatiramer acetate
- DRUG interferon beta 1-a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01071083
The ClinicalTrials.gov registry entry for NCT01071083 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which methylprednisolone is the first listed.
NCT01071083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01071083 about?
NCT01071083 is a clinical study titled "Treatment Interruption of Natalizumab". This is a randomized, rater blinded trial in patients who interrupt treatment with natalizumab with or without being treated with other immunomodulatory drugs, or continue treatment with natalizumab. The main purpose of this study is to find out the following, when participants stop taking natalizu...
What is the current status of trial NCT01071083?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2010-03. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01071083?
The interventions under investigation include: methylprednisolone (DRUG), natalizumab (DRUG), IV placebo (OTHER), glatiramer acetate (DRUG), interferon beta 1-a (DRUG).
Who is sponsoring clinical trial NCT01071083?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.